Real‐world treatment patterns and outcomes among patients with immune thrombocytopenia ( ITP ) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL ‐ AVA 3.5 study

Documents similaires

• Efficacy and safety of romiplostim and eltrombopag in management of thrombocytopenia in Wiskott–Aldrich syndrome patients
  par: Anna Ogneva, et autres
  Publié: (2025)
• Switching patients with immune thrombocytopenia ( ITP) to avatrombopag from other thrombopoietin receptor agonists: The real‐world experience of the Spanish ITP Group ( GEPTI )
  par: Cristina Pascual‐Izquierdo, et autres
  Publié: (2026)
• Efficacy and safety of eltrombopag in combination with dexamethasone as first‐line treatment in adult patients with newly diagnosed immune thrombocytopenia
  par: Annaïse J. Jauch, et autres
  Publié: (2026)
• Longitudinal plasma proteomics in romiplostim‐treated patients with immune thrombocytopenia
  par: Vivianne S. Nelson, et autres
  Publié: (2025)
• Anti‐ CD38 therapy in immune thrombocytopenia ( ITP )
  par: Waleed Ghanima, et autres
  Publié: (2026)